TD Cowen analyst Phil Nadeau has maintained their bullish stance on KZR stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Phil Nadeau has given his Buy rating due to a combination of factors related to Kezar Life Sciences’ recent developments and clinical trial results. The company reported positive outcomes from its Phase 2 trial of zetomipzomib in autoimmune hepatitis (AIH), where a significant percentage of patients achieved biochemical remission compared to the placebo group. This demonstrates the potential efficacy of the treatment, which is further supported by the acceptable safety profile observed in the trial.
Additionally, the FDA’s decision to lift the partial clinical hold on the AIH trial and the upcoming Type C meeting to discuss the pivotal trial design are promising steps forward for Kezar. These developments indicate a positive trajectory for the company’s drug pipeline, enhancing investor confidence in its future prospects. As a result, Nadeau’s recommendation reflects the potential for significant advancements and value creation in Kezar’s ongoing and future clinical programs.
According to TipRanks, Nadeau is a 3-star analyst with an average return of 2.7% and a 40.87% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Kura Oncology, Syndax Pharmaceuticals, and Biogen.